Rare diseases
Investigational molecules
Locations
Anti‑PD1 Therapy with pembrolizumab and cemiplimab in first‑line advanced non‑small cell lung cancer patients with high PD‑L1 expression
FranceA Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin
GermanyStudy of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back
BelgiumStudy of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment
FranceStudy of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments
HungaryStudy of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher
AustriaStudy of Cemiplimab Combined with Imiquimod and Laser Therapy Before Surgery for High-Risk Skin Basal Cell Carcinoma
SpainStudy on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab
FranceStudy on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)
ItalyStudy on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use
FranceStudy on Encorafenib, Binimetinib, Cemiplimab, and Fianlimab for Patients with BRAF-Mutated Melanoma and Brain Metastases
SpainStudy on Treating Advanced Non-Small Cell Lung Cancer with Cemiplimab and Chemotherapy Based on Blood Tumor DNA Levels
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.
